The effects of alaproclate on the pupillary responses to tyramine, phenylephrine and pilocarpine in depressed patients.
Nine depressed patients were treated with alaproclate, a selective 5-HT uptake inhibitor, for 3 weeks in a dose of 400 mg daily. The pupillary responses to tyramine, phenylephrine, and pilocarpine eye drops were measured on consecutive days before, after 1 week and after 3 weeks of treatment. The tyramine-induced mydriasis was unaffected by alaproclate, suggesting that it does not significantly inhibit the reuptake of noradrenaline. The pilocarpine-induced miosis and the phenylephrine-induced mydriasis were both enhanced after 1 week but not after 3 weeks of treatment. This suggests that alaproclate acutely increases the responsiveness of postsynaptic muscarinic and alpha 1 adrenoceptors.
D000409:Alanine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000928:Antidepressive Agents / Q000494:pharmacology*; D003866:Depressive Disorder / Q000503:physiopathology*; D005260:Female; D006801:Humans; D008297:Male; D010656:Phenylephrine / Q000494:pharmacology; D010862:Pilocarpine / Q000494:pharmacology; D011680:Pupil / Q000187:drug effects*; D012702:Serotonin Antagonists / Q000494:pharmacology; D013566:Sympathomimetics / Q000494:pharmacology*; D013997:Time Factors; D014439:Tyramine / Q000494:pharmacology
D000928:Antidepressive Agents; D012702:Serotonin Antagonists; D013566:Sympathomimetics; D010862:Pilocarpine; D010656:Phenylephrine; C025293:alaproclate; D000409:Alanine; D014439:Tyramine